Akebia Therapeutics, Inc. Cash Flow Statement
AKBA|10 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Akebia Therapeutics, Inc. generated $68M in operating cash flow and $68M in free cash flow in FY2025. Free cash flow margin was 28.7% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$279.7M | -$143.6M | -$73.7M | -$135.7M | -$13.2M | -$8.2M |
| Depreciation & Amortization | - | - | - | $1.7M | $2.2M | $899.0K | $617.0K | $296.0K | $1.0K | $0 |
| Operating Cash Flow | $68.0M | -$40.7M | -$23.4M | -$73.2M | -$257.4M | -$97.5M | -$56.2M | $57.9M | -$11.3M | -$7.2M |
| Capital Expenditures | $291.0K | $33.0K | $0 | $114.0K | $6.7M | $1.6M | $1.6M | $2.7M | $19.0K | $19.0K |
| Free Cash Flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | -$264.1M | -$99.1M | -$57.8M | $55.2M | -$11.4M | -$7.2M |
| Share Buybacks | - | - | - | - | - | - | - | - | $162.0K | $162.0K |
| FCF Margin | 28.7% | -25.4% | -12.0% | -25.1% | -78.8% | -47.7% | -31.9% | 3599.0% | - | - |